1.30Open1.30Pre Close0 Volume1 Open Interest130.00Strike Price0.00Turnover159.42%IV49.28%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry1.30Extrinsic Value100Contract SizeAmericanOptions Type-0.0290Delta0.0007Gamma195.18Leverage Ratio-0.1439Theta-0.0048Rho-5.66Eff Leverage0.0417Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet